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BODY:
Task 1: Define the molecular mechanism, including the structural details, by which CaM activates estradiol-dependent ERa transcription (Months 1-36).
The overall goal here is to describe, from a structural perspective, how CaM binding to ERa activates the receptor. Our principle structural tool is NMR spectroscopy. ERa and CaM (isotopically labeled and unlabeled) for NMR studies . We demonstrated previously ("Preliminary Results" of our proposal) the ability to produce a construct of ERa that includes the putative CaM binding region and the ligand binding domain of ERa (residues 286-552, see Figure 1 and Figure 2 for estrogen receptor structural organization), and we demonstrated that this construct binds CaM. We have also produced isotopically labeled samples of this ERa construct for preliminary NMR studies.
Subtask a). Produce
To date, we have not been able to record acceptable NMR spectra of isotopically labeled ERa (with either E2 or TAM bound) or the ERa-CaM complex (this concerns "Subtask b", below). Our goal was to produce ERa purified by affinity chromatography on immobilized CaM resin that had not been carboxymethylated with iodoacetic acid. Carboxymethylation of cysteine residues in ERa for structural studies has been adopted nearly universally, but we hoped to avoid this in order to more closely mimic the native state. We currently are pursuing an alternate production and purification strategy that incorporates cysteine carboxymethylation and affinity purification on estradiol sepharose. ). As discussed above under "Subtask a", we have not yet been able to record acceptable spectra of our ERa construct that includes the CaM binding domain and the ligand binding domain (residues 286-552), and we currently are pursuing an alternate ERa production and purification approach.
Subtask b). Perform NMR experiments on the complex between CaM and ERa with E2 (estrogen) bound and the CaM-ERa complex with TAM bound
We have also initiated a complementary, but more limited, approach to understanding some of the structural aspects of the interaction between ERa and CaM. In this approach we are defining the structural details of the complex of CaM with the CaM binding region only of Structural organization of the estrogen receptor dimer. The Xray crystal structure of the LBD (green) of ER with estrogen bound is from Gangloff et al. (2) (PDB identifier 1QKU). The X-ray crystal structure of the DBD (blue) of ER bound to DNA is from Schwabe et al. (5) (PDB identifier 1HCQ) . No high resolution structural information is available for the AF-1, AF-2 and hinge domains.
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ERa. In general, these types of studies of CaM interactions with binding domains from protein targets have been very successful (6, 7) . Thus, this approach will enable some of the important structural aspects of this interaction to be resolved.
The first undertaking for these studies was to confirm our localization of the CaM-binding region of ERa. Our strategy was to examine CaM binding to different segments of the hinge region of ERa (and N-terminal end of the ligand binding domain). In order to do this, we produced two constructs to study their interactions with CaM. The first was a protein construct consisting of the hinge region of ERa and the N-terminal end of the ligand binding domain (residues 241-320) fused to an affinity tag (His 6 -tag) and thioredoxin for solubility (Figure 3) . We call this protein Trx-ERA . We also produced a similar protein construct, but with only residues 241-273 of ERa, as a "control" (Figure 3 ). We call this protein Trx-ERA . Because CaM binds tightly to the N-terminal extended ligand binding domain of ERa (residues 286-552, see above), we hypothesized that Trx-ERA 241-320 would bind tightly to CaM, but that Trx-ERA would not. The genetic constructs encoding these proteins were subcloned into an appropriate expression vector for bacterial expression, and the proteins were produced in E. coli. Production and purification of Trx-ERA 241-320 is shown in Figure 4 . The His 6 tag enabled purification by immobilized metal affinity chromatography (IMAC). In the case of the longer protein, Trx-ERA 241-320 , we demonstrated tight, Ca 2+ -dependent binding to CaM, and this was incorporated into the purification protocol. Final purification was by reversed-phase HPLC, resulting in very pure protein for more detailed studies. Purification of Trx-ERA 241-273 was by IMAC only ( Figure 5 ).
Studies to verify Ca 2+ -dependent binding of CaM to are shown in Figure 6 . In the presense of Ca 2+ , Trx-ERA 241-320 binds very tightly to immobilized CaM (CaM-Sepharose 4B), and is not eluted even at very high ionic strength (1 M NaCl). Only when the Ca 2+ is chelated with EDTA, does Trx-ERA 241-320 elute from the resin (lane 8 of panel 'A'), demonstrating a tight, Ca 2+ dependent, specific interaction of Trx-ERA 241-320 with CaM. In the absence of Ca 2+ (panel 'B'), some nonspecific, ionic strength dependent binding is observed, with high ionic strength removing all Trx-ERA 241-320 from the resin (nearly all Trx-ERA , is removed by 100 and 200 mM NaCl, lanes 4 and 5). Controls were performed, both in the presence of Ca 2+ and its absence, using Sepharose 4B without immobilized CaM (panels 'C' and 'D'). No significant interactions of Trx-ERA 241-320 with the resin alone were observed. : SDS-PAGE assessment of the production and purification of Trx-ERA241-320. The gene encoding Trx-ERA241-320 was cloned into the pET-32a vector, which was then transformed into E. coli BL21(DE3)-RIL for expression. The bacterial were grown on M9 minimal media and induced with IPTG. The cells were lysed, and Trx-ERA241-320 was purified by IMAC chromatography, affinity chromatography with immobilized CaM in the presence of Ca 2+ (elution with EDTA), and HPLC with elution using an acetonitrile gradient. M=molecular weight marker lanes. Lane 1, crude lysate. Lane 2, following IMAC chromatography. Lane 3, following elution from the immobilized CaM column with EDTA. Lane 4, following final purification using HPLC. The results in Figure 6 indicate a tight, Ca 2+ -dependent interaction of Trx-ERA 241-320 with CaM. Based on these results, and the results above demonstrating that CaM binds tightly to the N-terminal extended ligand binding domain of ERa (residues 286-552, see above), we hypothesized that the high affinity binding site of ERa for CaM lies in the C-terminal half of the hinge region. To test whether the N-terminal part of the hinge region would bind tightly to CaM, we tested for binding of Trx-ERA 241-273 to CaM. These results are shown in Figure 7 . These experiments were performed precisely as those with Trx-ERA . A weak, ionic strength dependent interaction of Trx-ERA 241-320 is observed, both in the presence and absence of Ca
2+
(panels 'A' and 'B'). No interaction with the Sepharose 4B resin (without immobilized CaM) is observed (panels 'C' and 'D'). These results suggest the possibility of a weak interaction of CaM with this region of ERa. We cannot determine, at this stage, if this interaction is physiologically relevant. However, it is possible that, under some circumstances, this interaction might serve to sequester CaM to ERa (especially at low Ca 2+ levels) to raise the local CaM concentration and improve (speed up) the activation process when Ca 2+ levels spike. Based on the well-known propensity of CaM to bind to basic, amphiphilic regions, and based on our results (above) showing that CaM binds with high affinity to an ERa ligand binding domain located between residues 274 and 320 (see above), and we hypothesized the existence of a high-affinity CaM binding domain comprised of residues 287-311 of ERa (Figure 8) . We therefore performed experiments to verify if this peptide would bind with measurable affinity to , and the elution buffer is 20 mM Tris-HCl, pH 7.5, with 2 mM EGTA and 1 mM NaCl2. For 'B' and 'D', the equilibation buffer (and the buffer solution for the CaM is 20 mM Tris-HCl, pH 7.5, with 1 mM EDTA, and the "elution" buffer is 20 mM Tris-HCl, pH 7.5 with 1 M NaCl and 10 mM CaCl2. M=molecular weight markers. Lane 1, purified Trx-ERA241-320 protein in equilibration buffer. Lane 2, load flow-through. Lane 3, equilibration buffer. Lanes 4-7, equilibration buffer with 100, 200, 500, or 1000 mM NaCl, respectively. For 'A' and 'C', lane 8 is elution buffer. . These experiments were performed in a manner identical to those in Figure  6 . The panels here also correspond to those in Figure 6 .
CaM. We used a synthetic peptide corresponding to residues 287-311 of ERa (commercially synthesized), which we call HERA . For controls, we used a peptide corresponding to residues 295-311 of ERa (HERA [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] [311] ) and a peptide known to bind to CaM with very high affinity (dissociation constant in the nM regime) which corresponds to the CaM binding domain of the myosin light chain kinase (MLCK). These sequences are shown in Figure 8 . We first conducted simple electrophoretic mobility shift assays (EMSA) to determine the relative abilities of these peptides to form complexes with CaM in non-denaturing polyacrylamide gels ( Figure 9 ). The MLCK peptide binds very tightly to the CaM. The complex is clearly visible in the gel, little free CaM remains at a 1:1 ratio of peptide:CaM, and no free CaM is observed at higher ratios. Likewise, a complex between HERA 287-311 and CaM is observed even at low peptide:CaM ratios. The results indicate that the affinity of this complex is not as high as the MLCK:CaM complex. Finally we do not detect complex formation between the shorter HERA 295-311 peptide and CaM. This indicates that residues 287-294 contribute substantially to the affinity of ERa for CaM. This is important, because recent studies (8, 9) suggest that these residues, 295-311 of ERa, are the CaM binding domain, but this is clearly not correct or complete.
We currently are performing additional studies to characterize the binding of HERA to CaM. Because the amino acid sequence of HERA 287-311 includes a tryptophan residue, and because there are no tryptophan residues in CaM, we can use fluorescence spectroscopy, and intrinsic tryptophan 4-CaM. The spectra were acquired at various ratios of CaM:peptide (0:1 = no CaM, 3:1 = three fold molar excess CaM over peptide, etc.). The spectra are corrected by subtraction for the small background fluorescence of the added CaM. The excitation frequency was 295 nm. The spectra were acquired in a solutions consisting of 10 μM peptide, 0-30 μM CaM, 50 mM MOPS, 2 mM CaCl2, 100 mM KCl, pH 7.0. The temperature was 25 °C.
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fluorescence, to monitor the interaction of HERA and CaM. Likewise, the MLCK peptide sequence includes a single tryptophan residue, so, as a control, we can monitor binding of this peptide to CaM using fluorescence techniques also. In Figure 10 are shown fluorescence emission scans of HERA and the MLCK peptide as a function of added CaM. In both cases, the emission wavelength maxima shift to lower wavelengths when the peptides bind to CaM, and the emission intensity increases. These results signify that, in both cases, peptide binding to CaM results in the tryptophan becoming buried in a hydrophobic environment. For HERA , the intensity increase is particularly dramatic, indicating that the tryptophan residue is deeply buried in a hydrophobic environment (one of the hydrophobic clefts of the globular domains of CaM). These results indicate clearly that residues 287-294 (including the tryptophan residue at position 292) contribute to the interaction of ERa with CaM.
We currently are performing quantitative analyses of the interaction of HERA 287-311 and Ca (2:1) to the contrary (6) . Interestingly, inspection of the results in Figure 10 indicates that the increase in intensity observed when the HERA 287-311 :CaM ratio is only 0.5:1 is much higher than expected. This suggests that more than one HERA 287-311 peptide is binding to CaM, which suggests that the stoichiometry of the HERA 287-311 :CaM complex is 2:1 rather than 1:1. This could have very important implications with respect to the ERa:CaM stoichiometry and ERa activation by CaM. The studies to confirm the stoichiometry are ongoing.
We have initiated studies to determine a high resolution structure of the complex of HERA 287-311 and CaM (Ca 2+ 4 -CaM) using NMR. We have titrated 13 C, 15 N-labeled CaM with HERA 287-311 (again, the apparent stoichiometry suggested by this titration is 2:1) to produce a complex amenable for study. A comparison of the 2D 1 H, 15 N-HSQC NMR spectra of free CaM and CaM bound to HERA 287-311 , which reflect the structural differences of free CaM and CaM bound to HERA , are shown in Figure 11 . Because the signals in the spectrum of free CaM are assigned, it is clear that structural elements from all parts of the molecule are changed when HERA 287-311 binds. Moreover, the spectrum of the complex indicates that the complex is homogeneous in solution, and that determining a high resolution structure using NMR will not be problematic.
Using standard triple resonance assignment methods (HNCA, HN(CO)CA, HNCACB, CB(CACO)NH, etc.) we have assigned the main chain nuclei (and 13 C ) of Ca 4 -CaM bound to HERA . This has allowed us to calculate the chemical shift changes of the nuclei of CaM that accompany HERA 287-311 binding, and thus to begin the process of understanding the structural changes that take place in CaM upon HERA 287-311 binding. For the assigned nuclei, we have calculated the chemical shift changes, and have also calculated a weighted average over all assigned nuclei (Figure 12) . Overall, the chemical shift changes are somewhat smaller than those observed when CaM binds to prototypical, canonical tight binding sequences, such 4-CaM, both free in solution (black contours) and bound to HERA287-311 (red contours) are shown. The concentrations of CaM and HERA287-311 are 0.5 and 1.5 mM, respectively, and the buffer solution is 5 mM d4-imidazole, 10 mM KCl, 10 mM CaCl2, pH 6.5, with 5% D2O for an instrumental lock. The spectra were acquired at 25 °C and 600 MHz ( 1 H). The spectrum of the complex indicates it to be structurally homogeneous and amenable to continued study by NMR. The chemical shift changes throughout CaM resulting from HERA287-311 binding indicate structural changes throughout CaM as the MLCK peptide (1). In the case of HERA 287-311 binding, the chemical shift changes suggest that the collapse of CaM around the peptide(s) is not as dramatic as that observed, for instance, for the MLCK peptide, reflecting, perhaps, crowding due to the presence of two bound peptides (assuming the 2:1 stoichiometry discussed above). We also note some unusual, very large changes in the C-terminal domain (M109 in helix VI, M144 in helix VIII) signifying important structural changes in the C-terminal binding pocket.
Many, and in fact most, calmodulin binding domains of target proteins are basic, amphiphilic, and form helices when bound to calmodulin (10) . Using circular dichroism, we monitored the helicity of CaM and the complex of Ca indicates that the HERA 287-311 peptide adopts a helical structure when bound to CaM. The results indicate that the HERA 287-311 peptide is not helical when free in solution, but adopts a helical structure when bound to CaM (Figure 13) . The results suggest that CaM binding to ERa induces helical structure in the CaM binding domain. Presumably, this contributes to the activation process, but precisely how remains to be determined. . This subtask is due to begin in year 2. We anticipate calculating structures of CaM with bound HERA , and hope to be calculating structures of CaM bound to HERA 286-522 . The plot at the bottom shows an absolute value weighted average (1) calculated by normalizing the absolute value of each shift change by the absolute value of the largest change for that nucleus and then averaging for each position. The secondary structure is also shown (dark bars represent alpha helices and light bars beta strands), determined using chemical shift index (CSI) analysis (3, 4) . The overall goal here is to determine if oxidative stress and oxidation of CaM resulting from oxidative stress can mediate the complex between CaM and ERa and antiestrogen resistance.
Subtask c). Calculate structures of the complexes using standard NMR computational methods and software

Subtask a). Produce ERa and wildtype and mutant CaM proteins (isotopically labeled and unlabeled) for NMR, gel shift, and SPR studies (Months 6-18).
As discussed above, we have produced lots of these proteins for these stated purposes. We will undoubtedly produce more in the following year for remaining studies.
Subtask b). Perform NMR experiments on the complex between CaM and TAM (Months 6-24).
Our studies on this complex to date are represented mostly by those shown as preliminary results in the proposal. Because of the importance of the experiments for Task 1, we focused on those experiments. We will continue with more studies of the CaM-TAM complex in the next year.
Subtasks c-f).
These subtasks are all due to begin in the next year.
Task 3: Test and describe the direct link between PKA induced antiestrogen resistance and CaM binding to ERa (Months 12-36).
The goal of this task is to test the hypothesis that posttranslational modifications in the CaM binding region of ERa mediate the interaction, and how this might contribute to antiestrogen resistance. [12] [13] [14] [15] . This subtask is complete. In addition to HERA287-311 phosphorylated at Ser 305, we have a peptide acetylated at Lys 302, and another acetylated at Lys 303. These peptides will be tested for their affinity for CaM relative to the unmodified peptide, and they will be tested for their abilities to induce structural changes in CaM when they bind (again, relative to wild type).
Subtask a). Obtain synthetic peptides corresponding to the CaM binding domain of ERa and phosphorylate at Ser 305 (Months
Subtask b). Produce ERa and CaM (isotopically labeled and unlabeled) for NMR and SPR experiments (Months 12-18).
Subtasks c-e).
KEY RESEARCH ACCOMPLISHMENTS:
• Residues 286-552 of ERa, which includes the entire ligand binding domain and the putative calmodulin binding domain, does indeed bind calmodulin. One of our goals, ultimately, is to determine the structural changes in the ligand binding domain of ERa that occur when calmodulin binds, and how these contribute to receptor activation. To date, we have not made as much progress towards this goal as we would have liked, but we have demonstrated that we can produce and purify this protein construct, and that it does bind to calmodulin (calmodulin affinity purification is the last step of the purification protocol). These studies are continuing with the goal of using this protein for NMR spectroscopy studies of the structural changes that occur in ERa when calmodulin binds and how these contribute to ERa activation.
•
The calmodulin binding region(s) of ERa reside(s) in amino acid residues 241-320.
Using an affinity tagged 241-320 (hinge region of ERa) construct (Trx-ERA 241-320 ), we demonstrated high affinity, calcium dependent binding to calmodulin.
• A high affinity, calcium-dependent calmodulin binding site of ERa is further localized to residues 287-311. Using a peptide synthesized by solid-phase methods (HERA 287-311 ) , we have demonstrated a high affinity, calcium-dependent binding of calmodulin to residues 287-311 of ERa. The amino acid sequence represents a non-canonical calmodulin binding region, but nevertheless shares many of the properties of traditional high affinity calmodulin binding sites (basic, amphiphilic, probably helical).
• A shorter region of ERa ) does not represent the full calmodulin binding region. An independent investigation by another research group has suggested that residues 295-311 of ERa constitute the calmodulin binding region. Our results indicate that this is incorrect. Firstly, our fluorescence results unequivocally demonstrate that W292 is buried in a hydrophobic pocket of one of the globular domains of calmodulin (this residue is not present in the shorter peptide). Secondly, we have compared directly the relative affinities of the longer and shorter peptides, and the shorter peptide clearly displays a much lower affinity for calmodulin.
An additional, low affinity calmodulin binding region includes residues 241-273 of ERa.
We have determined that a second, lower affinity calmodulin binding region of ERa is localized to regions 241-273 (hinge region) of ERa. We are unsure currently whether this represents a physiologically relevant site or simply non-specific binding. However, an additional site could assist in maintaining a high local concentration of calmodulin for ERa activation.
• The high affinity calmodulin binding region of ERa contains three residues subject to posttranslational modifications that can potentially mediate calmodulin affinity. Residues S305, K302 and K303 of ERa have all been shown to be posttranslationally modified (the serine phosphorylated, the lysines acetylated). Calmodulin binds to basic (and amphiphilic) domains, so increasing the negative charge in this region (phosphorylating the serine) or decreasing the positive charge (acetylating the lysines) would be expected to decrease the affinity for calmodulin. Thus, it appears that nature has chosen to mediate ERa activation by attenuating calmodulin affinity by posttranslational modification.
• The interaction of the ERa peptide ) with calmodulin results in structural changes in calmodulin that suggest that the crowding from two bound peptides limits the structural collapse of calmodulin around the bound peptides and that unusual structural changes are occurring in the C-terminal binding pocket. Using NMR spectroscopy, we have determined how the chemical shifts of calmodulin change when the ERa calmodulin binding peptide binds. The changes indicate that, compared to complexes of calmodulin with other high affinity targets, the complex of calmodulin with the ERa peptide is extended rather than collapsed. We suggest that this is due to crowding from the two bound peptides. We also observed some large, notable and atypical chemical shift changes in the C-terminal globular domain of calmodulin suggesting some novel structural attributes. We are in the process of determining a high resolution structure of this complex using NMR spectroscopy.
• The calmodulin binding region of ERa ) adopts helical structure when bound to calmodulin. Most calmodulin binding regions of target proteins adopt (basic, amphiphilic) helical character when they bind to calmodulin. The ER peptide is no exception. In the absence of calmodulin, circular dichroism indicates a total lack of helical structure, but the peptide clearly adopts helical structure when bound to calmodulin.
• Oxidation of the methionine residues in calmodulin results in the inability of calmodulin to bind to tamoxifen and hydroxytamoxifen. It has been conjectured that the beneficial consequences of tamoxifen therapy for estrogen dependent breast cancers results from the binding of tamoxifen to calmodulin, which inhibits the ability of calmodulin to activate the receptor. Under conditions of high oxidative stress in breast cancer tissues, if the methionine residues in calmodulin are oxidized, tamoxifen no longer binds to calmodulin. This could be one mechanism by which antiestrogen resistance could develop.
• The inability of oxidized calmodulin to bind tamoxifen/hydroxytamoxifen is due to altered polarity of the tamoxifen binding sites on calmodulin. Control experiments show that replacement of all methionine residues in calmodulin with leucine does not substantially alter tamoxifen binding. Therefore, the polarity changes induced by oxidation of the methionine residues in calmodulin to methionine sulfoxide most likely is the cause of the results observed.
REPORTABLE OUTCOMES:
Abstracts/Presentations:
We are currently completing some of the studies for two journal submissions that include results based on work funded by this CDMRP award. Results of these studies have been presented in a poster presentation at a local/regional scientific meeting/conference and are scheduled for presentation at two additional national conferences this summer (full abstracts for these presentations appear in the "APPENDICES" section below): 
Education/Training/Employment/Research Opportunities:
To date, five undergraduate students, from both UGA, neighboring institutions, and institutions outside of the Southeast, have participated in, or are currently participating in, this project in my laboratory and have received important scientific training both in basic protein biochemistry and in cancer biology. These students (listed below) are all pursuing professional careers in science and medically related fields.
I'll also note that five of these students are co-authors of at least one of the presentations listed above and most, if not all, will be co-authors on planned journal submissions. Likewise, a Postdoctoral Researcher in my laboratory, Dr. Carrie Jolly, is currently working on various aspects of this project. Dr. Jolly is also preparing a Postdoctoral Fellowship Grant application to be submitted later this year to the NIH and other federal and private funding sources. Dr. Jolly has designed and currently is initiating a project distinct from, but closely related to, our DOD/CDMRP project. She will continue to work on our project, and if her fellowship is funded, she will pursue the goals of her fellowship application. Thus, our DOD/CDMRP project is contributing in important ways to advanced postdoctoral training, in assisting to help develop the scientific career of Dr. Jolly, and has stimulated considerable scientific synergy.
CONCLUSION and "SO-WHAT" section:
Knowledge of the precise binding site or sites for CaM on ERa is essential ultimately for understanding, from a structural and mechanistic perspective, how calmodulin binding to ERa activates ERa. Because it is apparent that the C-terminal end of the CaM binding domain is part of the ligand binding domain of ERa, CaM binding most likely affects the structure of the ligand binding domain, and therefore the current mechanisms for E2 activation and antiestrogen inactivation are at least incomplete if not incorrect. Furthermore, recent studies have "localized" the CaM binding domain to a short section of the hinge region, and we have demonstrated that this is incorrect. In addition, we have found what appears to be a second, lower affinity CaM binding site in the N-terminal region of the hinge, which appears to be Ca 2+ -independent. This could have important implications for CaM binding and ERa activation, and could represent a mechanism to sequester CaM at low Ca 2+ levels in order that activation (when Ca 2+ spikes) is rapid.
CaM binding domains of dozens of proteins activated by CaM are most always basic, amphiphilic, and adopt helical structure when bound to CaM. The high affinity site that we have localized on ERa appears similar in these respects. The more rigid helical structure often adopted by these domains is integral to the mechanism of activation, and often represents the first, obligatory step in the activation process. Thus, it is critical to understand these structural changes in order to define mechanistically how activation occurs. In the same vein, the structural changes that occur in CaM when it binds to these domains is also important. These changes may be very large, as is the case for binding to the MLCK (discussed above), or smaller, as is the case for ERa. This is important, as it signifies that a large scale "collapse" of CaM around the high affinity domain in ERa is less dramatic, and reflects fundamantal structural attributes associated with the activation process, In the case of ERa, we suspect that these more modest structural changes result from the fact that CaM can bind to two CaM binding domains of ERa simultaneously, and that the crowding resulting from the presence of two peptides does not permit a dramatic collapse, as is observed for MLCK (for instance).
Our hypothesis is that CaM and oxidative stress are integral to the process of antiestrogen development. Our rationale is as follows. It has been suggested that tamoxifen (TAM) binding to CaM blocks CaM activation of ERa, and therefore contributes positively to tamoxifen therapy for estrogen dependent breast cancer. The oxidative stress level (and levels of reactive oxygen species) in breast cancer tissue is high, and because the methionine residues in CaM are easily oxidized, we tested whether oxidized CaM could still bind TAM. It does not. If oxidized CaM can still bind and activate ERa, then TAM would not be able to as effectively inhibit CaM activation of ERa when CaM is oxidized. Thus, this would be a mechanism for development of antiestrogen resistance. We currently are in the process of determining how CaM oxidation affects binding to ERa, and whether or not our hypothesis, as described here, is valid.
Overall, our studies to date have been very successful and informative. We have established a very firm foundation for continuing the work that we originally proposed.
Estrogen dependent breast cancers require the transcriptional activation activity of the estrogen receptor alpha (ERa). These account for approximately 70% of all breast cancers. In response to estrogen binding, a set of genes is activated by ERa. This facilitates growth and propagation of the cancer cells. The important calcium-binding signaling protein calmodulin (CaM) binds ERa, and, recently, it was demonstrated that CaM is essential for activation of ERa transcriptional activity. Here we present progress towards defining the CaM binding region of ERa and the structural changes in CaM upon interaction with ERa, and towards understanding potential cellular mechanisms for mediating activation of ERa by CaM. As a first step towards elucidating the mechanism of ERa activation by CaM, we have produced a segment of the ERa protein (residues 241-320) as a thioredoxin fusion and demonstrated binding to CaM. A short, 25 amino acid section of this segment of ERa, suspected to comprise the CaM binding sequence, was produced, as were three derivatives containing modifications known to occur naturally. Fluorescence titration experiments demonstrated that these peptides all bind to CaM, and they all bind with rare 2:1 (peptide:CaM) stoichiometries. Their relative binding affinities are consistent with established principles for CaM interactions with target domains. The complex of CaM with the wild-type peptide was studied using NMR spectroscopy. The chemical shifts of CaM were assigned using triple resonance methods. Estrogens and estrogen receptor alpha (ERa) are central to estrogen-dependent breast cell carcinoma induction and proliferation. ERa is the principal target for systemic endocrine/antiestrogen therapy, underscoring its biological relevance and medical importance. Recently, it was established that calcium-dependent activation by calmodulin (CaM) is essential for estrogen-dependent ERa activity and that the active species is the CaM-ERa complex. CaM also binds tightly to antiestrogens, including the most widely used chemotherapeutic agent for estrogen-dependent breast cancers, tamoxifen (TAM). The therapeutic effects of antiestrogens are indicated to be due, in part, to CaM antagonism. Our objectives include establishing the molecular mechanism whereby CaM activates estradiol-dependent ERa transcription and defining the role of oxidative stress in mediating CaM-ERa and CaM-antiestrogen interactions. We have localized the CaM binding region of ERa to a 25 amino acid segment in the ERa hinge region and have initiated NMR spectroscopy studies to determine the structure of the complex of CaM with this CaM binding region. Based on chemical shift changes, the collapse of CaM around the ERa CaM binding domain is much less dramatic than observed for complexes of CaM with prototypical binding domains, with relatively large structural changes occur in the Cterminal domain of CaM. These results suggest that CaM bound to ERa is more extended structurally compared to typical CaM complexes and signify important structural changes in the C-terminal binding pocket of CaM. Oxidation of the methionine residues in CaM eliminates binding to TAM and hydroxy-TAM. TAM binding to mutant CaM where all methionine residues are replaced by leucine is unaffected by the leucine substitutions. Methionine oxidation results in polarity changes that decrease the affinity of CaM for hydrophobic drugs. The results are important for a comprehensive understanding of CaM activation of ERa and the link between oxidative stress and development of antiestrogen resistance. Recently it has been established that calcium-dependent activation by calmodulin (CaM) is essential for estrogen-dependent ERa activity, and that the active species is the CaM-ERa complex (Li, L., Li, Z., and Sacks, D. B. (2005) J Biol Chem 280, 13097-104.) . CaM also binds tightly to antiestrogens, including the most widely used chemotherapeutic agent for estrogendependent breast cancers, tamoxifen (TAM). The therapeutic effects of antiestrogens, like those of other CaM antagonists, are indicated to be due, in part, to the direct interaction with CaM.
Oxidative stress -estrogen-induced oxidative stress and constitutive oxidative stressis indicated in estrogen-dependent breast cancer tissues. Oxidative stress is also implicated as mediating development of resistance of breast cancers to antiestrogens. TAM is also implicated in inducing a potent oxidative stress response in breast cancer tissue. It has been demonstrated in other oxidatively stressed tissues (senescent brain), that increased levels of reactive oxygen species and the failure of cellular repair mechanisms conspire to cause accumulation of oxidized CaM species (where one or more of the nine methionine residues are oxidized to the sulfoxides), altering intracellular calcium homeostasis. Oxididation of CaM can reduce its ability to activate some target proteins, without necessarily reducing binding affinity. Because there are nine methionine residues in CaM, most of which interact with the CaM binding domains of target proteins, the effects of oxidation can be specific for particular methionine residues. Our objectives include establishing the molecular mechanism, including the structural details, by which CaM activates estradiol-dependent ERa transcription, and defining the role of oxidative stress in mediating CaM-ERa and CaM-antiestrogen interactions. Towards these goals we have localized the CaM binding region of ERa to a 25 amino acid segment in the hinge region of ERa. We have initiated studies using NMR spectroscopy to determine the structure of the complex of CaM with this CaM binding region of ERa. To date, based on chemical shift changes, we have found the collapse of CaM around the ERa CaM binding domain is much less dramatic than observed for complexes of CaM with prototypical binding domains, and that relatively large structural changes occur in the C-terminal domain of CaM. Oxidation of the methionine residues in CaM eliminates binding to TAM and hydroxy-TAM. TAM binding to CaM with all methionine residues replaced by leucine is unaffected by the leucine substitutions. These results suggest that CaM bound to ERa is more extended structurally compared to typical CaM complexes and signify important structural changes in the C-terminal binding pocket of CaM. Oxidation of methionine residues in CaM results in polarity changes that decrease the affinity of CaM for hydrophobic drugs. The results will be important for a comprehensive understanding of the principles governing CaM activation of ERa and the link between oxidative stress and development of antiestrogen resistance, in order to aid in the design and development of a new pharmaceuticals to treat breast cancers.
CV:
A cv is attached, following the "Supporting Data" section
SUPPORTING DATA:
All figures are embedded in the text (above), along with their respective figure legends. 
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